CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation–induced cell death in hepatocellular carcinoma

Guo‐Dong Lu, Yang Huey Ang, Jing Zhou, Jegadeesan Tamilarasi, Benedict Yan, Yaw Chyn Lim, Supriya Srivastava, Manuel Salto‐Tellez, Kam M. Hui, Han‐Ming Shen, Long N. Nguyen, Bryan C. Tan, David L. Silver, Shing Chuan Hooi – 1 November 2014 – CCAAT enhancer binding protein α (C/EBPα) plays an essential role in cellular differentiation, growth, and energy metabolism. Here, we investigate the correlation between C/EBPα and hepatocellular carcinoma (HCC) patient outcomes and how C/EBPα protects cells against energy starvation.

Clinical outcomes of and patient satisfaction with different incision methods for donor hepatectomy in living donor liver transplantation

Suk‐Won Suh, Kwang‐Woong Lee, Jeong‐Moo Lee, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh – 28 October 2014 – With the decrease in the average donor age and the increase in the proportion of female donors, both donor safety and cosmetic appearance are major concerns for some living donors in living donor liver transplantation (LDLT) because a large abdominal incision is needed that may influence the donor's quality of life. In all, 429 donors who underwent donor hepatectomy for LDLT from April 2010 to February 2013 were included in the study.

Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection

Georgios Grammatikos, Nerea Ferreiros, Dimitra Bon, Stephanie Schwalm, Julia Dietz, Caterina Berkowski, Daniel Fitting, Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, Josef Pfeilschifter – 28 October 2014 – Ablation of very‐long‐chain ceramides (Cers) with consecutive elevations in sphinganine levels has been shown to cause a severe hepatopathy in a knockout mouse model. We have recently shown that serum sphingolipids (SLs) are deregulated in patients with chronic liver disease. However, their role as possible biomarkers in liver fibrosis remains to date unexplored.

Invasive aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases

Francesco Barchiesi, Susanna Mazzocato, Sara Mazzanti, Rosaria Gesuita, Edlira Skrami, Alessandro Fiorentini, Nina Singh – 28 October 2014 – Invasive aspergillosis (IA) in liver transplant recipients is associated with grave outcomes. We reviewed 116 individual cases reported in the literature from 1985 to 2013. IA was diagnosed after a median of 25 days after transplantation and involved a single organ in 51% of the cases, whereas in the remaining cases, multiple sites were involved.

Subscribe to